Rytelo imetelstat

Drug Class

Telomerase inhibitor

Mechanism

Binds directly to the RNA component of telomerase (hTR) to inhibit enzymatic activity, suppressing expansion of malignant hematopoietic clones.

Approved Indication

Treatment of adult patients with low- to intermediate-1-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or are ineligible for erythropoiesis-stimulating agents (ESAs).

What This Means For Patients

Rytelo is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2024) — Sources

Pivotal Clinical Evidence

• IMerge — Platzbecker et al., Lancet 2024 (NCT02598661) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217755s000lbl.pdf